( June 10, 2025, 3:46 PM EDT) -- TAMPA, Fla. — Novo Nordisk Inc. on June 9 urged a Florida federal court to amend its order granting summary judgment in favor of a pharmaceutical company accused of selling unapproved compounded drugs containing semaglutide XE "semaglutide" , arguing that because the court held that the drug manufacturer’s claims were moot, the court erred in analyzing the merits of the case and should amend the judgment to dismiss the case without prejudice....